Mirion Technologies, Inc. (NYSE: MIR) is a Industrials company (Industrial - Machinery) with a market capitalization of $4.1B. The Maz Rating grades it against the other companies in its sector.
About three months ago (August 17, 2026), Mirion Technologies, Inc. had a Maz Rating of 2.73 out of 5 (C+, Hold), ranked against the other companies in its sector. Its strongest factor then was Growth (4.56), among the strongest in its sector; its weakest was Valuation (1.53), more expensive than most of its sector. The other factors: Profitability 3.49 (around the middle of its sector); Financial Health 3.09 (around the middle of its sector); Momentum 1.83 (below most of its sector). The current rating is for members: log in to see it.
At $16.65, Mirion Technologies, Inc. trades at 143.3x trailing earnings, 3.8x sales and 2.3x book value, with an EV/EBITDA of 21.6. Over the last twelve months it generated about $1.1B of revenue and $29M of net income. It runs a gross margin of 48.1%, an operating margin of 6.0% and a net margin of 2.7%. It shows return on equity of 1.6%, return on invested capital of 1.5% and a free cash flow yield of 4.2%. On the balance sheet: a debt-to-equity ratio of 0.70 and a current ratio of 3.02. Over the past 52 weeks the share price ranged from $14.04 to $27.49, with a beta of 1.07.
Mirion Technologies, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Mirion Technologies, Inc. (MIR) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 30.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.1% / 30% · Interest income / Revenue 0.97% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 30.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.6% / 33% · Receivables / Mkt Cap (36m) 7.16% / 49% · Interest income / Revenue 0.97% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 30.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.6% / 33.33% · Receivables / Mkt Cap (24m) 7.16% / 33.33% · Interest income / Revenue 0.97% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 34.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 11.8% / 33.33% · Receivables / Avg Assets (4Q) 8.12% / 33.33% · Interest income / Revenue 0.97% / 5% | Fail |
| FTSE | Debt / Total Assets 34.3% / 33.33% · (Cash+ST Inv) / Total Assets 11.9% / 33.33% · (Cash+Recv) / Total Assets 19.9% / 33.33% · Interest income / Revenue 0.97% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Mirion Technologies, Inc. (MIR) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global and Dow Jones, and fails AAOIFI, MSCI and FTSE.
No. Mirion Technologies, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.97% of each dividend: Mirion Technologies, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.